Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Conatus Pharmaceuticals Inc. (NASDAQ: CNAT).

Full DD Report for CNAT

You must become a subscriber to view this report.


Recent News from (NASDAQ: CNAT)

Conatus And Emricasan In NASH Cirrhotic Portal Hypertension: The Overlooked Therapeutic Promise
"Nothing can dim the light that shines from within" - Maya Angelou Introduction Conatus Pharmaceuticals ( CNAT ) is a small cap ($52M) clinical stage biopharma. Emricasan, a dual anti-apoptotic/anti-inflammatory oral irreversible pan-caspase inhibitor, is its lead investigative P...
Source: SeekingAlpha
Date: December, 10 2018 05:59
A Look Into Conatus' Failed ENCORE-PH Trial
Conatus (CNAT) is a clinical-stage biotech company that is developing a pan-caspase protease inhibitor, emricasan, with Novartis' ( NVS ) help. Emricasan is undergoing 4 different trials, 3 of which are focused on non-alcoholic steatohepatitis ((NASH)). On December 5, 2018, it announced top-li...
Source: SeekingAlpha
Date: December, 07 2018 18:03
Conatus May Still Have A Path Forward After Latest Phase 2b Data
Recently, Conatus Pharmaceuticals ( CNAT ) announced results from its phase 2b ENCORE-PH study treating patients with NASH cirrhosis portal hypertension. The primary endpoint for the overall trial wasn't met. However, I believe that the company still has a path forward for a subpopulation ...
Source: SeekingAlpha
Date: December, 07 2018 08:50
Today's Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Titan Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / Conatus Pharmaceuticals and Titan Pharmaceuticals were both seeing gains in Friday’s trading session. There was no news to explain Titan shares jumping but Conatus reported third quarter results and an update on its trials last week. RD...
Source: ACCESSWIRE IA
Date: November, 05 2018 08:00
Key events next week - healthcare
Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 02 2018 10:12
Conatus Pharma Q3 revenues down 20%
Conatus Pharmaceuticals ( CNAT ) Q3 results: Revenues: $7.7M (-19.8%). More news on: Conatus Pharmaceuticals, Healthcare stocks news, Earnings news and commentary, , Read more ...
Source: SeekingAlpha
Date: November, 02 2018 06:28
Conatus Pharmaceuticals (CNAT) CEO Steve Mento on Q3 2018 Results - Earnings Call Transcript
Conatus Pharmaceuticals (CNAT) Q3 2018 Earnings Conference Call November 01, 2018, 04:30 PM ET Executives Alan Engbring - Executive Director of IR and Corporate Communications Steve Mento - President and CEO Keith Marshall - EVP, COO and CFO Analysts Yasmeen Rahimi - ROTH C...
Source: SeekingAlpha
Date: November, 01 2018 22:18
Conatus Pharmaceuticals EPS in-line, misses on revenue
Conatus Pharmaceuticals (NASDAQ: CNAT ): Q3 GAAP EPS of -$0.15 in-line. Revenue of $7.66M (-19.9% Y/Y) misses by $2.12M . Press Release More news on: Conatus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: November, 01 2018 16:12
Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates
SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and nine months ended September 30, ...
Source: GlobeNewswire
Date: November, 01 2018 16:05
Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results
SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the third quarter ended September 30, 2018, after the market close on Thursday, November 1, 2018. Conatus will host a conference call and audio w...
Source: GlobeNewswire
Date: October, 25 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-141.521.5251.591.50750,423
2018-12-131.651.5051.651.49730,299
2018-12-121.641.611.681.5554841,289
2018-12-111.551.61991.751.531,700,856
2018-12-101.721.511.721.491,740,570

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14158,623396,74039.9816Short
2018-12-1394,211194,50248.4370Short
2018-12-1288,005407,78521.5812Cover
2018-12-11293,708616,41447.6478Short
2018-12-10264,326658,28440.1538Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CNAT.


About Conatus Pharmaceuticals Inc. (NASDAQ: CNAT)

Logo for Conatus Pharmaceuticals Inc. (NASDAQ: CNAT)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CNAT)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 03 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 02 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 27 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 04 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 09 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 07 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 06 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 05 2018
      Annual statement of changes in beneficial ownership of securities
      Filing Type: 5Filing Source: edgar
      Filing Date: February, 05 2018

       

       


      Daily Technical Chart for (NASDAQ: CNAT)

      Daily Technical Chart for (NASDAQ: CNAT)


      Stay tuned for daily updates and more on (NASDAQ: CNAT)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CNAT)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CNAT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CNAT and does not buy, sell, or trade any shares of CNAT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/